Sarpogrelate
Sarpogrelate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C, and 5-hydroxytryptamine receptor 2A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | — | 1 | 3 | — | 5 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 1 | 2 | — | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 2 | — | 3 |
| Coronary disease | D003327 | — | — | — | — | — | 2 | — | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | 2 | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | 1 | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 2 | — | 2 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | — | 1 | 1 | 2 |
| Intermittent claudication | D007383 | EFO_0003876 | I73.9 | — | — | — | 1 | 1 | 2 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral infarction | D002544 | — | I63 | — | — | 2 | — | — | 2 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 2 | — | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 8 | — | — | — | — | 8 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Arteriosclerosis obliterans | D001162 | EFO_1000820 | — | — | — | — | — | 1 | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sarpogrelate |
| INN | sarpogrelate |
| Description | Sarpogrelate is a stilbenoid and a hemisuccinate. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 125926-17-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL52939 |
| ChEBI ID | — |
| PubChem CID | 5160 |
| DrugBank | — |
| UNII ID | 19P708E787 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HTR2B
HTR2B
HTR2C
HTR2C
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2B
Gene synonyms
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2B
Protein synonyms
5-HT 2B receptor, 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled, 5-hydroxytryptamine 2B receptor, Serotonin receptor 2B
Uniprot ID
Mouse ortholog
Htr2b (15559)
5-hydroxytryptamine receptor 2B (Q9QWS2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 617 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
92 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use